Knockdown of Ki-67 by Dicer-Substrate Small Interfering RNA Sensitizes Bladder Cancer Cells to Curcumin-Induced Tumor Inhibition

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Pichu, Sivakamasundari ^a   Krishnamoorthy, Swapna ^a   Shishkov, Andrei ^a   Zhang, Bi ^a   McCue, Peter ^a   Ponnappa, Biddanda C ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; DICER SUBSTRATE SMALL INTERFERING RNA; KI 67 ANTIGEN; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KI 67 GENE; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; RATS; RIBONUCLEASE III; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

CURCUMA LONGA; RATTUS;

EID: 84869059093     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048567     Document Type: Article

References (40)

1. Parker SL, Tong T, Bolden S, Wingo PA (1996) Cancer Statistics. CA Cancer J Clin: 5-27.
2. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO, (1995) Apparent failure of current intravesical chemotherapy prophylaxis to influence long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153: 1444-1450.
3. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global Cancer Statistics, 2002. CA Cancer J Clin 55: 74-108.
4. Herr HW, Donat SM, Reuter VE, (2007) Management of low grade papillary bladder tumors. J Urol 178: 1201-1205.
5. Guhasarkar S, Banerjee R, (2010) Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. J Control Release 48: 147-159.
6. Sylvester RJ, Oosterlinck W, Van der Maijden AP, (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage TaT1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171: 2186-2190.
7. Raghavan D, Quinn D, Skinner DG, Stein JP, (2002) Surgery and adjunctive chemotherapy for invasive bladder cancer. Surg Oncol 11: 55-63.
8. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811.
9. Hannon GJ, (2002) RNA interference (review). Nature 418: 244-251.
10. Dorsett Y, Tuschl T, (2004) siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 3: 318-29.
11. Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, et al. (2010) A status report on RNAi therapeutics. Silence 1: 1-14.
12. Gondi CS, Rao JS, (2009) Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol 220: 285-291.
13. Ponnappa BC, (2009) siRNA for inflammatory diseases (Review). Curr Opin Investig Drugs 10: 418-424.
14. MacCallum DE, Hall PA, (1999) Biochemical characterization of pKi-67 with the identification of a mitotic-specific form associated with hyper phosphorylation and altered DNA binding. Exp Cell Res 252: 186-198.
15. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, et al. (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715.
16. Yao R, Yi Y, Grubs CJ, Lubet RA, You M, (2007) Gene expression profiling of chemically induced rat bladder tumors. Neoplasia 9: 207-221.
17. Kausch I, Lingnau A, Endl E, Sellman K, Deinert I, et al. (2003) Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. Int J Cancer 105: 710-716.
18. Blietz CE, Thode B, Hauses M, Pries R, Meyer AJ, et al. (2009) In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer. In vivo 23: 13-20.
19. Zheng JN, Ma TX, Cao JY, Sun XQ, Chen JC, et al. (2006) Knockdown of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells. Life Sciences 78: 724-729.
20. Reis LO, Pereira TC, Favaro WJ, Cagnon VHA, Lopes-Cendes I, et al. (2009) Experimental animal model and RNA interference: a promising association for bladder cancer research. World J Urol 27: 353-361.
21. Lingnau A, Steiner U, Kurzidim H, Jocham D, Kausch I, et al. (2010) Phase I dose-escalation study of intravesical instillation of antisense oligonucleotide FFC15-01 against Ki-67 in patients with non-muscle invasive bladder cancer. Debates on Bladder Cancer 2: 1.
22. Brantl S, (2002) Antisense-RNA regulation and RNA interference. Biochim Biophys Acta 1575: 15-25.
23. Jing Y, Shishkov A, Ponnappa BC, (2008) Inhibition tumor necrosis factor alpha secretion in rat Kupffer cells by siRNA: In vivo efficacy of siRNA-liposomes. Biochem Biophys Acta 1780: 34-40.
24. Kim DH, Behlke MA, Rose SD, Chang M-S, Choi S, et al. (2005) Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotech 23: 222-226.
25. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, et al. (2011) A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 68: 157-164.
26. Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, et al. (2011) Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 28: 1937-55.
27. Sethi G, Sung B, Aggarwal BB (2009) The role of curcumin in modern medicine. In: Ramawat KG, editor. Herbal Drugs: Ethnomedicine to Modern Medicine. Berlin Heidelberg: Springer-Verlag. 97-112.
28. Shehzad A, Wahid F, Lee YS, (2010) Curcumin in cancer chemoprevention: Molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm Chem Life Sci 9: 489-499.
29. Aggarwal BB, Kumar A, Bharti AC, (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23: 363-398.
30. Tharakan ST, Inamoto T, Sung B, Aggarwal BB, Kamat AM, et al. (2009) Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers. Biochem Pharmacol 79: 218-228.
31. Kamat AM, Sethi G, Aggarwal BB, (2007) Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulations of nuclear factor-kappa B and nuclear factor-kappa B- regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Therapeut 6: 1022-1030.
32. Xiao Z, McCallum TJ, Brown KM, Miller GG, Halls SB, et al. (1999) Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Brit J Cancer 81: 638-646.
33. Plumb JA, (2004) Cell Sensitivity Assays: The MTT Assay. Methods Mol Med 88: 165-169.
34. Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G, (2002) Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 512: 334-340.
35. Ravindran J, Prasad S, Aggarwal BB, (2009) Curcumin and Cancer Cells: How many ways can curry kill tumor cells selectively. The AAPS Journal 11: 495-510.
36. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, et al. (2005) Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappa B and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 280: 6301-6308.
37. Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, et al. (2007) Sethi G. Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol 73: 1024-1032.
38. Tian B, Wang Z, Zhao Y, Wang D, Li Y, et al. (2008) Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Letters 264: 299-308.
39. Tang H, Zhao K, Pizzolato JF, Fonarev M, Langer JC, et al. (1998) Constitutive expression of the Cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53. J Biol Chem 273: 29156-29163.
40. Liu S, Bishop WR, Ming L, (2003) Differential effects of cell cycle regulatory protein p21waf/Cip1 on apoptosis and sensitivity to cancer chemotherapy. Drug Resist updates 6: 183-195.